These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8256796)

  • 21. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
    Landman JO; Hamdy NA; Pauwels EK; Papapoulos SE
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3465-8. PubMed ID: 8530584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.
    Li LJ; Zhang J; Gao P; Lv F; Song YW; Chang XY; Zhao DC; Wang O; Jiang Y; Xing XP; Xia WB; Li M
    Clin Rheumatol; 2018 Nov; 37(11):3141-3150. PubMed ID: 29946989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bisphosphontes].
    Ichimura S
    Clin Calcium; 2005 Apr; 15(4):583-90. PubMed ID: 15802769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
    Woo T; Adachi JD
    Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
    Miki T; Minamide T
    Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
    Delmas PD; Recker RR; Chesnut CH; Skag A; Stakkestad JA; Emkey R; Gilbride J; Schimmer RC; Christiansen C
    Osteoporos Int; 2004 Oct; 15(10):792-8. PubMed ID: 15071723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diphosphonates in the treatment of osteoporosis].
    Papapoulos S
    Ther Umsch; 1991 Feb; 48(2):100-6. PubMed ID: 1903565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A; Adachi J; Olszynski W
    CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
    Liu CL; Lee HC; Chen CC; Cho DY
    Clin Invest Med; 2017 Jun; 40(3):E146-E157. PubMed ID: 28653616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis and its complications.
    Varacallo MA; Fox EJ
    Med Clin North Am; 2014 Jul; 98(4):817-31, xii-xiii. PubMed ID: 24994054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.